2022. Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s48. DOI:https://doi.org/10.25251/skin.6.supp.48.